Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT: Tepotinib + Gefitinib in MET+ EGFR-mutant NSCLC
NCT01982955Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Merck KGaA. Primary endpoints: Dose Limiting Toxicity, Treatment-Emergent Adverse Events up to 175 weeks and 1 more. Started Dec 2013; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01982955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982955.